Quick Answer
Theravance Biopharma, Inc. reported Total Revenue of $107.46 million for fiscal year 2025.
Theravance Biopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $107.46M +66.9% |
$64.38M +12.1% |
$57.42M +11.8% |
$51.35M -7.2% |
$55.31M -23.0% |
$71.86M -2.1% |
| Revenue (ASC 606) | $107.46M +66.9% |
$64.38M +12.1% |
$57.42M +11.8% |
$51.35M -7.2% |
$55.31M -23.0% |
$71.86M -2.1% |
| Net Income | $105.89M +287.7% |
-$56.42M -2.2% |
-$55.19M -106.3% |
$872.13M +537.3% |
-$199.43M +28.3% |
-$278.02M -17.6% |
| Diluted EPS | $2.06 +279.1% |
-$1.15 -15.0% |
-$1.00 -108.4% |
$11.85 +512.9% |
-$2.87 +35.7% |
-$4.46 -4.9% |
| Total Assets | $485.57M +37.1% |
$354.16M -7.3% |
$382.00M -37.1% |
$607.40M +62.1% |
$374.82M -20.1% |
$469.06M +14.7% |
| Cash and Equivalents | $167.81M +344.0% |
$37.80M -4.4% |
$39.55M -86.7% |
$298.17M +231.5% |
$89.96M +10.4% |
$81.47M +40.3% |
| Stockholders Equity | $296.72M +69.0% |
$175.54M -17.6% |
$213.00M -51.8% |
$441.80M +230.5% |
-$338.57M -11.5% |
-$303.75M -35.7% |
| R&D Expense | $37.41M -0.6% |
$37.64M -7.3% |
$40.62M -35.9% |
$63.39M -67.3% |
$193.66M -25.8% |
$260.95M +19.0% |
| Operating Income | -$3.60M +92.3% |
-$46.95M +16.2% |
-$56.03M +39.1% |
-$91.96M +64.3% |
-$257.78M +13.4% |
-$297.63M -18.1% |
| Shares Outstanding | 51.07M +3.2% |
49.47M +2.9% |
48.09M -26.3% |
65.23M -12.4% |
74.44M +15.7% |
64.33M +12.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $19.99M | +18.5% | -23.7% |
| Revenue (ASC 606) | September 30, 2025 | $19.99M | +18.5% | -23.7% |
| Net Income | September 30, 2025 | $3.62M | +128.5% | -93.4% |
| Diluted EPS | September 30, 2025 | $0.07 | +126.9% | -93.5% |
| Total Assets | September 30, 2025 | $415.46M | +16.7% | -2.5% |
| Cash and Equivalents | September 30, 2025 | $174.77M | +647.6% | -38.0% |
| Stockholders Equity | September 30, 2025 | $232.68M | +25.3% | +3.5% |
| R&D Expense | September 30, 2025 | $8.11M | -12.5% | -22.7% |
| Operating Income | September 30, 2025 | -$6.46M | +40.4% | -136.9% |
| Shares Outstanding | September 30, 2025 | 50.67M | +3.0% | +0.6% |
- Theravance Biopharma, Inc. reported Total Revenue of $107.46 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +66.9% in Total Revenue compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Revenue (ASC 606) of $107.46 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +66.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Net Income of $105.89 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +287.7% in Net Income compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Diluted EPS of $2.06 per share for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +279.1% in Diluted EPS compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Total Assets of $485.57 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +37.1% in Total Assets compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Cash and Equivalents of $167.81 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +344.0% in Cash and Equivalents compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Stockholders Equity of $296.72 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +69.0% in Stockholders Equity compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported R&D Expense of $37.41 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed a decrease of -0.6% in R&D Expense compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Operating Income of -$3.60 million for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +92.3% in Operating Income compared to the prior fiscal year.
- Theravance Biopharma, Inc. reported Shares Outstanding of 51.07 million shares for fiscal year 2025.
- Theravance Biopharma, Inc. showed an increase of +3.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: